






This article discusses the global importance and multifactorial nature of the 
growing antimicrobial resistance (AMR) threat. It outlines how resistance arises 
at the level of the bacterium; including intrinsic and acquired resistance mecha-
nisms. It also assesses current approaches to tackling AMR, both in the UK and 
worldwide, such as: drug development, calls for changes to medical, industrial 
and legislative practices, and antimicrobial-stewardship.
Relevance
With increasing numbers of multidrug resistant organisms causing infections 
worldwide, medical students must enter the workforce equipped with an under-
standing of the severity and origins of this situation as well as an appreciation of 
the steps being taken, and which they themselves can take as future clinicians, to 
address this challenge. 
Take Home Messages
AMR is a multifactorial and continually evolving threat with its origins in the 
inherent genetic properties of microbes and their evolutionary nature. Conse-
quentially, whilst urgent action is needed to combat an AMR problem exac-
erbated in recent decades, AMR will always persist. As microbes continually 
evolve new survival strategies, it is essential to continue to develop new pharma-
cological agents in conjunction with new practices and policies on institutional, 
national and international scales to protect global public health from the threat 
posed by AMR.  
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Antibiotics were classically de!ned in 1947 by S. A. Waksman as 
natural substances that inhibit the growth of, or destroy, bacteria. 
In the current literature “antibiotic” may refer to any antimicrobial 
substance (toxic to viruses, fungi, protozoa or bacteria) that has 
natural, synthetic, or other origins. (1) Since the development of 
modern antibiotics in the early part of the 20th Century mortality 
from infectious diseases has declined signi!cantly; illustrated by the 
8.2% average annual decrease in infectious disease mortality in the 
USA from 1938 to 1952. (2) This was seen at the time as revolu-
tionary, however contemporary optimism was to be undermined 
by the emergence of antimicrobial resistance (AMR).  The current 
challenges and grave potential consequences posed by AMR to 
healthcare provision mean that it is essential for medical students, as 
future clinicians, to have an appreciation of the origins, causes and 
implications of AMR. In addition to addressing these issues, this 
article will discuss current strategies for tackling AMR both in the 
UK and around the world.
AMR describes the emergence of pathogen strains which have 
developed an immunity or resistance to antimicrobial drugs which 
previously had been lethal to that species. It is a consequence of 
evolution by natural selection and is exacerbated by the increased 
selection pressure applied to microbes by overuse of antibiotics. 
AMR is a rapidly developing problem which poses a signi!cant 
threat to global health. (3)   
AMR is not a new phenomenon. In his Nobel Prize lecture in 1945 
Alexander Fleming himself warned of the risks of resistance stating 
that it was possible to produce resistant bacteria by exposing them 
to non-lethal concentrations of penicillin. (4) However, the scale 
and severity of the problem has grown in recent decades.  
The bacteria identi!ed as presenting the greatest AMR threat, and 
the causes of the majority of nosocomial infections worldwide, 
are collectively termed the “ESKAPE Pathogens” (summarised in 
Table 1). The English Surveillance Programme for Antimicrobial 
Utilisation and Resistance (ESPAUR) have reported increases in 
the incidence of bacteraemia caused by each of the ESKAPE patho-
gens each year since 2014.(6) The global scale of the risk posed by 
these organisms, and others such as Mycobacterium tuberculosis, 
was summarised !ve years ago in a report by the World Health Or-
ganisation (WHO). (5) They reported that carbapenem-resist-
ant Klebsiella pneumoniae is now present in all regions of the world, 
with carbapenem drugs ine"ective in up to 50% of patients in some 
countries. They also report that in 2014 there were approximately 
480 000 cases of multidrug-resistant Tuberculosis. 9.7% of these 
cases were Extensively Drug-Resistant Tuberculosis caused by M. 
tuberculosis which is resistant to four di"erent antibiotics and found 
in 105 countries. In terms of global impact; the O’Neill Report 
estimates that by 2050, AMR related deaths will reach 10 million 
per year with an economic impact of up to $100 trillion. (3) 
Table 1: 
ESKAPE Pathogens and the reported rate of bacteraemia attributed to these 
species according to the ESPAUR report 2018 to 2019 (6)
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Intrinsic Resistance 
Some bacteria have intrinsic resistance to antibiotic drugs. This 
includes bacteria which lack the molecular targets of a speci!c anti-
biotic, and those with innate e#ux mechanisms or cell walls which 
are highly impermeable. (7) Bacteria have varied and complex outer 
membranes composed of phospholipids and lipopolysaccharides 
meaning that they have varying susceptibility to cell wall acting 
antibiotics such as beta-lactams. Additionally, widely varied cell 
wall permeability found within gram-negative bacteria makes the 
discovery of e"ective antibiotics particularly challenging. (8)
Acquired Resistace 
Unlike intrinsic resistance, acquired resistance mechanisms are not 
inherent properties of a given bacterial species – they are assimilated 
through random genetic mutation, from other bacteria or from the 
environment. (9)
Horizontal gene transfer (HGT) is one of the most prevalent strate-
gies for conferring or acquiring AMR in bacteria. HGT involves 
the exchange of mobile genetic elements, containing ‘resist-
ance genes’, between bacteria. Extra-chromosomal plasmids and 
conjugative transposons - which integrate into the genome of the 
recipient bacterium, can be transferred by conjugation or transfor-
mation. (10) AMR genes can also be acquired via bacteriophages 
through transduction, or through intra-genomic rearrangement, for 
example, involving insertion sequences. (11) Acquired AMR may 
also arise spontaneously through genetic mutation. For example, 
micro-organisms such as Helicobacter pylori have acquired resist-
ance to Fluoroquinolones and Clarithromycin through mutation. 










Enterococcusௗfaeciumௗ Positive - -
Staphylococcus aureusௗ Positive 19.4 23.2 19.59%
Klebsiellaௗpneumoniaeௗ Negative 9.1 12.1 32.97%
Acinetobacter spp. Negative 1.3 1.5 15.38%
Pseudomonasௗspp.ௗ Negative 6.4 7.6 18.75%





Acquired AMR mechanisms fall into three groupings:  
• Prevention of the antibiotic accessing the target molecule within 
the bacterium 
• Changes to this target molecule 
• Direct modi!cation or destruction of the antibiotic.  
Bacteria may prevent antibiotics reaching their molecular targets by 
either decreasing permeability or by increasing e#ux of the antibi-
otic. Decreased permeability may be achieved through the down 
regulation of transmembrane channels known as porins. Decreased 
porin expression has been shown to contribute to AMR in several 
species of Acinetobacter, Enterobacteraciaeae and Pseudomonas. 
(9) Increasing the e#ux of an antibiotic can be achieved through 
the expression of e#ux pumps. E#ux pumps are transmembrane 
structures which actively remove both endogenous and exogenous 
substances from the bacteria cytosol which are present across a wide 
variety of species. The use of these pumps to speci!cally remove 
antibiotics has been documented as a cause of AMR in many bacte-
rial species including important human pathogens such as Legionel-
la spp. and Brucella spp. (14)
Changes to the targets of antimicrobial agents by mutation, modi!-
cation or protection of the target can all confer AMR. An example 
is resistance to Linezolid, an antibiotic which targets 23S ribosomal 
RNA subunits (rRNA). Most bacteria possess multiple copies of 
this gene and even single base-pair mutations have been shown to 
produce 23S rRNA which is impervious to Linezolid action, for 
example in Staphylococcus species. (15) Another way in which bac-
teria may protect their ribosomal components from antibiotic action 
is through methylation. The erm genes encode an enzyme which 
methylates both 23S and 50S rRNA subunits, impairing the ability 
of antibiotics such as macrolides to bind to these molecules. (16) 
The third group of acquired AMR mechanisms is the direct 
modi!cation or destruction of antibiotic drugs. The expression 
of enzymes for hydrolytic inactivation of antibiotics is a strategy 
employed by numerous bacterial species, for example, lactamase en-
zymes expressed by a variety of bacteria including Enterobac-
teriaceae. (17) Additionally, bacteria may modify antibiotics by 
adding chemical moieties such as nucleotides or phosphate groups 
to them thus reducing their ability to bind to their targets. Due to 
their chemical structure aminoglycoside antibiotics are particularly 
vulnerable to enzymatic modi!cation by bacteria. (9) 
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One of the most prominent publications detailing strategies for 
combatting the rise in AMR is the O’Neill report commissioned 
by the UK Government in 2014 to investigate the threat posed by 
AMR and recommend international actions to address the problem. 
(3)  The report’s recommendations include strategies to reduce the 
need for antimicrobials by reducing infectious disease spread. Such 
strategies involve: increasing global public awareness, improving 
hygiene including access to clean water and sanitation and increased 
vaccination. Preventing infection will clearly reduce use of antimi-
crobials, reducing the rate of AMR development and preserving the 
utility of existing antimicrobial agents. (18) The UK is now is the 
middle of a !ve-year action plan (2019 to 2024) which builds upon 
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This plan echoes many of the recommendations in the O’Neill 
report; its “three key ways” of tackling AMR are reduced antimi-
crobial exposure, optimised use and investment in innovation.
Antimicrobial Stewardship 
In addition to reducing the overall need for antibiotics, the concept 
of antimicrobial-stewardship aims to optimise antibiotic prescribing 
through directing their use to only evidence based, appropriate in-
dications. Some aspects of antimicrobial-stewardship have attracted 
controversy in recent years. Many studies have reported the bene!ts 
of these practices for slowing AMR development and improving 
patient outcomes. (20) However, some publications have suggested 
that actions such as delaying the start of antimicrobial treatment 
and early treatment de-escalation may have negative impacts on 
patient outcomes. Fitzpatrick et al. (21) discuss the “tension” 
between antimicrobial-stewardship and sepsis prevention. This may 
force clinicians and policy makers into di$cult decisions between 
administering antibiotics for the potential bene!t of the patient 
or withholding antibiotics for the potential bene!t of the wider 
population. Furthermore, mathematical modelling by Obolski and 
colleagues suggests that restricting the use of antimicrobials may ac-
tually lead to increased emergence of multidrug resistant pathogens. 
(22).  This may be due to, or exacerbated by, reduced antimicro-
bial prescribing leading to an increase in ‘sub-lethal’ exposure of 
bacterial populations to antibiotics and thus yielding more e"ective 
selection and exacerbating the AMR problem.
Rapid Diagnostics 
Rapid diagnostics to reduce unnecessary antimicrobial use and 
target the use of narrow spectrum drugs, is a further proposal of the 
O’Neill Report, (3) and one which is already being appraised for 
use in clinical settings, with a range of positive and negative !nd-
ings. Researchers have predicted the useful life of current last line 
antibiotics for Neisseria gonorrhoeae could be extended by point-
of-care susceptibility testing – i.e. taking a patient sample, culturing 
the organism then testing its susceptibility to various antibiotics 
before deciding which one to prescribe , potentially postponing 
the situation where gonorrhoea becomes untreatable with current 
antibiotics. (23) On the other hand, in 2018 the National Institute 
for Health and Care Excellence (NICE) investigated point-of-care 
testing for Streptococcus A infection in patients presenting with 
sore throats. Their resultant brie!ng describes 11 tests, and states 
that there is “limited evidence” that such testing would change 
current antibiotic prescribing practices. (24) In November 2019 
this research was incorporated into their Diagnostics Guidance in 
which they do not recommend this kind of rapid diagnostic testing 
for people aged over 5 years with sore throat symptoms. (25)  The 
reasons are that Group A Streptococcus is not the only bacterial 
cause of sore throat symptoms, and that these symptoms are o%en 
self-limiting and thus rapid diagnostic testing of this nature does not 
represent pragmatic, cost-e"ective practice. Therefore, these NICE 
recommendations represent a more nuanced assessment of not just 
test accuracy and validity but also how testing !ts into the broader 
clinical picture – a factor which is an important consideration for all 
novel testing practices. 
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Innovation and Development 
Both the O’Neill Report and The UK Government’s 5-year plan 
also advocate incentives for research and development of novel 
antimicrobials. (3,19) Suggestions include a Global AMR Innova-
tion Fund of over $2 billion, market entry rewards and improved 
industry incentives. Such suggestions are designed to counteract a 
well-documented slump in the number of new antibiotics that have 
come to market in recent decades.  Since the 1980’s drug com-
panies have increasingly shunned antimicrobial research in favour 
of more lucrative treatments for chronic and non-communicable 
diseases. (26) A further disincentive for novel antimicrobial research 
and design is reservation of novel drugs for second and third-line 
usage. Whilst this exempli!es good antimicrobial stewardship, it 
curtails the opportunity for pharmaceutical companies to generate 
pro!t and recoup development costs. For example, ce%aroline was 
added to the “Reserve Group” of antibiotics for “last resort” use in 
The WHO’s List of Essential Medicines within 7 years of licencing 
by the Federal Drug Administration. (27,28) Many commentators 
have cited the lack of new antimicrobials as an exacerbating factor 
for the global AMR crisis. (29) 
O’Neill’s recommendations in this arena are supported by other 
publications calling for global changes to drug development, (3) 
licensing and funding policies in order to remove obstacles and 
incentivise large pharmaceutical companies to re-engage with anti-
microbial research and development. (30) Legislative changes in the 
last decade give rise to hope that institutions and governments are 
taking note and enacting some of the demanded changes; however, 
there is limited evidence of the e"ectiveness of these measures and 
thus a need for greater international coordination. (31) 
There are a multitude of ways to quantify and predict the future im-
pact and costs of AMR including patient impact, impact on health-
care providers, the wider economic burden, and the perspective that 
any given study or prediction chooses to take can signi!cantly alter 
their !ndings. (32) This variability is part of the reason that current 
health-economic models are unable to accurately incorporate the 
wider societal costs of increasing AMR.
Optimism can be drawn from several promising avenues of re-
search into new drugs to treat resistant microbes. One such area is 
antibiotic adjuvants, also referred to as antibiotic resistance break-
ers (ARBs). ARBs are substances which increase or prolong the 
e"ectiveness of existing antimicrobial drugs by inhibiting bacterial 
resistance strategies. (33) lactamase enzyme inhibitors are among 
the oldest ARBs. Several decades of research have brought many 
candidate drugs into clinical trials although few have succeeded to 
clinical utility. Those which have made it to market include drugs 
which have improved the e"ectiveness of lactam antibiotics against 
resistant bacteria. (34)
In addition to preserving and improving existing drugs, novel 
classes of antibiotics are being discovered and investigated. Teixo-
bactin is perhaps the most salient of the novel antibiotics currently 
in development. Teixobactin was discovered using an exciting 
new technology known as iChip, a device which can both cap-
ture traditionally unculturable environmental bacteria and collect 
the potential antibiotic compounds produced by these bacteria. 
(35) Teixobactin kills Gram-positive bacteria by binding to lipid 
molecules and inhibiting cell wall synthesis. Teixobactin and its 
analogues currently look promising in preclinical trials, for example 
proving to be e"ective treatments for methicillin-resistant S. au-
reus in murine models. (35) Additionally, review of the literature 
by Wright et al.  found that ce!derocol, for example, is a promising 
novel antibiotic for the treatment of Gram-negative infections such 
as Pseudomonas aeurginosa. (36) However, these compounds have 
a long way to go through the clinical trials process before potentially 
reaching clinical utility. 
It is also worth noting that almost all antibiotics are either natural 
microbial products or synthetic derivatives of microbial products. 
These phenotypic molecules, expressed in the context of evolu-
tion and natural selection, are complex and thus di$cult to modify, 
replicate or synthesise on industrial scale. (37) Another implication 
is that these molecules exist due to an evolutionary race between 
microbes and thus antibiotic resistance long predates the clinical use 
of antimicrobial drugs. As a result, the potential for resistance to 
emerge to any novel compound exists long before that drug reaches 
clinical utility. (38)
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Antimicrobial drugs have been one of the major medical achieve-
ments of recent centuries. However, the emergence of AMR and 
its increase in both prevalence and clinical signi!cance in recent 
decades threatens to return us to an era of increased morbidity and 
mortality from infectious diseases. The mechanisms underpinning 
AMR are complicated, multifactorial and continually develop-
ing. Furthermore, the evolutionary nature of AMR means that 
resistance is likely to pose a challenge to all future antimicrobial 
drugs.  
Increasing recognition among the medical and scienti!c communi-
ties matched by political will and increasing awareness and action 
by governments and global institutions, such as the WHO, have 
brought us action plans and strategies to combat the AMR crisis. 
Whether these plans can be implemented successfully and in an ap-
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